Cardiovascular Complications of Hematopoietic Stem Cell Transplantation

被引：34
作者：
Blaes A. [1 ]
Konety S. [2 ]
Hurley P. [1 ]
机构：
[1] Division of Hematology/Oncology/Transplantion, University of Minnesota, 420 Delaware Street, S.E., MMC 480, 55455, Minneapolis, MN
[2] Division of Cardiology, University of Minnesota, Minneapolis, MN
来源：
Current Treatment Options in Cardiovascular Medicine | 2016年 / 18卷 / 4期
关键词：
Arrhythmias; Cardiac complications; Congestive heart failure; Stem cell transplantation; Survivors;
D O I：
10.1007/s11936-016-0447-9
中图分类号：
学科分类号：
摘要：
Survivors of hematopoietic stem cell transplant (HSCT) are at significant risk for cardiac disease and cardiac complications. While there may be cardiac complications during the acute period of HSCT, long-term survivors remain at risk for cardiovascular disease at a rate at least fourfold higher than the general population. Aggressive screening for cardiac risk factors such as diabetes, hypertension, and arrhythmias is warranted pretransplant. For those with risk factors, particularly a history of cardiovascular disease or atrial fibrillation, cardiology consultation is warranted in the pretransplantation period. Aggressive screening for cardiac risk factors such as diabetes, hypertension, and hyperlipidemia is warranted in HSCT survivors as well; early and aggressive treatment of left ventricular dysfunction is warranted. Collaboration between hematology/oncology and cardiology through a cardio-oncology clinic is an optimal way to help manage these patients. © 2016, The Author(s).
引用
收藏
页码：1 / 10
页数：9
相关论文
共 61 条
[1]  
(2014)
[2]  
Tonorezos E.S., Stillwell E.E., Calloway J.J., Et al., Arrhythmias in the setting of hematopoietic cell transplants, Bone Marrow Transplant, 50, pp. 1212-1216, (2015)
[3]  
Murdych T., Weisdorf D.J., Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977–1997, Bone Marrow Transplant, 28, pp. 283-287, (2001)
[4]  
Singla A., Hogan W.J., Ansell S.M., Et al., Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation, Biol Blood Marrow Transplant, 19, pp. 1233-1237, (2013)
[5]  
Peres E., Levine J.E., Khaled Y.A., Et al., Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation, Bone Marrow Transplant, 45, pp. 149-152, (2010)
[6]  
Sureddi R.K., Amani F., Hebbar P., Et al., Atrial fibrillation following autologous stem cell transplantation in patients with multiple myeloma: incidence and risk factors, Ther Adv Cardiovasc Dis, 6, pp. 229-236, (2012)
[7]  
Goldberg M.A., Antin J.H., Guinan E.C., Rappeport J.M., Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor, Blood, 68, pp. 1114-1118, (1986)
[8]  
Hertenstein B., Stefanic M., Schmeiser T., Et al., Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant, J Clin Oncol, 12, pp. 998-1004, (1994)
[9]  
Mills B.A., Roberts R.W., Cyclophosphamide-induced cardiomyopathy: a report of two cases and review of the English literature, Cancer, 43, pp. 2223-2226, (1979)
[10]  
Gottdiener J.S., Appelbaum F.R., Ferrans V.J., Deisseroth A., Ziegler J., Cardiotoxicity associated with high-dose cyclophosphamide therapy, Arch Intern Med, 141, pp. 758-763, (1981)
1234567